Kobayashi Junji, Nohara Atsushi, Kawashiri Masa-aki, Inazu Akihiro, Koizumi Junji, Nakajima Katsuyuki, Mabuchi Hiroshi
Department of Lipidology, Kanazawa University Graduate School of Medical Science Takara-machi 13-1, Kanazawa 920-8640, and Department of General Medicine, Kanazawa University Hospital, Japan.
Clin Chim Acta. 2007 Mar;378(1-2):7-12. doi: 10.1016/j.cca.2006.12.003. Epub 2006 Dec 13.
Lipoprotein lipase (LPL) is a lipolytic enzyme involved in catalyzing hydrolysis of triglycerides (TG) in chylomicrons and very low-density lipoprotein (VLDL) particles. Over the last decade, increasing attention has been paid to the clinical significance of measuring serum LPL protein mass without heparin injection to the study subjects. In earlier studies, this marker was utilized to classify LPL deficient subjects, which is an extremely rare metabolic disorder with a frequency of one in one million. Later, researchers paid more attention to the clinical significance of measuring this parameter in more common metabolic disorders. Studies have shown that pre-heparin plasma or serum LPL mass has significant relationships with serum lipids and lipoproteins, visceral fat area, insulin resistance, and even the development of coronary atherosclerosis in cross-sectional studies, although this might be a metabolic surrogate marker with almost no catalytic activities, which does not appear to be involved in catalyzing hydrolysis of TG in TG-rich lipoproteins. Recently, a prospective study has demonstrated that low serum LPL concentration predicts future coronary events. Taken together, we suggest that pre-heparin LPL mass in plasma or sera provide us with useful and important information on the development of metabolic disorders leading to atherosclerotic disease.
脂蛋白脂肪酶（LPL）是一种脂解酶，参与催化乳糜微粒和极低密度脂蛋白（VLDL）颗粒中的甘油三酯（TG）水解。在过去十年中，在研究对象不注射肝素的情况下测量血清LPL蛋白质量的临床意义受到了越来越多的关注。在早期研究中，该标志物被用于对LPL缺乏症患者进行分类，这是一种极其罕见的代谢紊乱疾病，发病率为百万分之一。后来，研究人员更加关注在更常见的代谢紊乱中测量该参数的临床意义。横断面研究表明，肝素前血浆或血清LPL质量与血清脂质和脂蛋白、内脏脂肪面积、胰岛素抵抗，甚至冠状动脉粥样硬化的发展都有显著关系，尽管这可能是一个几乎没有催化活性的代谢替代标志物，似乎不参与催化富含TG的脂蛋白中的TG水解。最近，一项前瞻性研究表明，低血清LPL浓度可预测未来的冠状动脉事件。综上所述，我们认为血浆或血清中的肝素前LPL质量为我们提供了有关导致动脉粥样硬化疾病的代谢紊乱发展的有用且重要的信息。
